SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

B. Riley FBR Downgrades Galmed Pharmaceuticals to Neutral, Lowers Price Target of $8

B. Riley FBR analyst Mayank Mamtani downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Neutral and lowers the price target from $11 to $8.

Benzinga · 05/22/2020 10:03

B. Riley FBR analyst Mayank Mamtani downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Neutral and lowers the price target from $11 to $8.